Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial.

Scientific reports - 28 Nov 2019

Gómez-Silva Magdalena, Piñeyro-Garza Everardo, Vargas-Zapata Rigoberto, Gamino-Peña María Elena, León-García Armando, de León Mario Bermúdez, Llerena Adrián, León-Cachón Rafael B R

Abstract excerpt

Amfepramone (AFP) is an appetite-suppressant drug used in the treatment of obesity. Nonetheless, studies on interindividual pharmacokinetic variability and its association with genetic variants are limited. We employed a pharmacokinetic and pharmacogenetic approach to determine possible metabolic phenotypes of AFP and identify genetic markers that could affect the pharmacokinetic variability in a Mexican...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Metabolic Clearance Rate

Share to Pharmacogenomic Variants

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 31780765
DOI: 10.1038/s41598-019-54436-z
PMCID: PMC6882847

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial.PMID 31780765Read ↗

Population pharmacokinetics of omeprazole in obese and normal-weight adults.Semantic proximity Read ↗

The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.Semantic proximity Read ↗

CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study.Semantic proximity Read ↗

Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine-to-Caffeine Metabolic Ratio: A Pharmacokinetic Study.Semantic proximity Read ↗

Current status of anti-obesity medications and performance, an EHR based surveySemantic proximity Read ↗

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.Semantic proximity Read ↗

Impact of Obesity and Bariatric Surgery on Metabolic Enzymes and P-glycoprotein Activity using Geneva Cocktail ApproachSemantic proximity Read ↗

Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach.Semantic proximity Read ↗

Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations.Semantic proximity Read ↗

Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort.Semantic proximity Read ↗

Pharmacogenetics of obesity drug therapy.Semantic proximity Read ↗

Pharmacogenetics of Olanzapine MetabolismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.